A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction

Eusebio Rubio-Aurioles, Hartmut Porst, Edward D. Kim, Francesco Montorsi, Geoff Hackett, Antonio Martin Morales, Bronwyn Stuckey, Hartwig Buttner, Teena M. West, Ngan N. Huynh, Enrique Lenero, Patrick Burns, Vladimir Kopernicky

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aim. To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5mg once a day (OaD) vs. tadalafil 20mg or sildenafil 100mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men ≥18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were analyzed with a mixed effects model for crossover design. Main Outcome Measures. The primary outcome measure was the Sexual Self-Confidence domain of the Psychological and Interpersonal Relationship Scales (PAIRS) between tadalafil OaD and sildenafil PRN. Secondary Outcomes Included. Time Concerns and Spontaneity domains of PAIRS, and the Self-Esteem and Relationship (SEAR) scale. Results. Men naive to tadalafil OaD were enrolled (N=378), with 61-69% prior PDE5 inhibitor use. There were improvements in all PAIRS domains from baseline when comparing tadalafil OaD and PRN with sildenafil PRN (P

Original languageEnglish
Pages (from-to)1418-1429
Number of pages12
JournalJournal of Sexual Medicine
Volume9
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Erectile Dysfunction
Phosphodiesterase 5 Inhibitors
Psychology
Cross-Over Studies
Outcome Assessment (Health Care)
Self Concept
Sildenafil Citrate
Tadalafil

Keywords

  • As needed
  • Erectile dysfunction
  • On-demand
  • Once a day
  • Pharmacotherapy for erectile dysfunction
  • Sildenafil
  • Tadalafil

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction. / Rubio-Aurioles, Eusebio; Porst, Hartmut; Kim, Edward D.; Montorsi, Francesco; Hackett, Geoff; Morales, Antonio Martin; Stuckey, Bronwyn; Buttner, Hartwig; West, Teena M.; Huynh, Ngan N.; Lenero, Enrique; Burns, Patrick; Kopernicky, Vladimir.

In: Journal of Sexual Medicine, Vol. 9, No. 5, 05.2012, p. 1418-1429.

Research output: Contribution to journalArticle

Rubio-Aurioles, Eusebio ; Porst, Hartmut ; Kim, Edward D. ; Montorsi, Francesco ; Hackett, Geoff ; Morales, Antonio Martin ; Stuckey, Bronwyn ; Buttner, Hartwig ; West, Teena M. ; Huynh, Ngan N. ; Lenero, Enrique ; Burns, Patrick ; Kopernicky, Vladimir. / A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction. In: Journal of Sexual Medicine. 2012 ; Vol. 9, No. 5. pp. 1418-1429.
@article{35262c92af184ffbb79c1786e38439c4,
title = "A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction",
abstract = "Aim. To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5mg once a day (OaD) vs. tadalafil 20mg or sildenafil 100mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men ≥18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were analyzed with a mixed effects model for crossover design. Main Outcome Measures. The primary outcome measure was the Sexual Self-Confidence domain of the Psychological and Interpersonal Relationship Scales (PAIRS) between tadalafil OaD and sildenafil PRN. Secondary Outcomes Included. Time Concerns and Spontaneity domains of PAIRS, and the Self-Esteem and Relationship (SEAR) scale. Results. Men naive to tadalafil OaD were enrolled (N=378), with 61-69{\%} prior PDE5 inhibitor use. There were improvements in all PAIRS domains from baseline when comparing tadalafil OaD and PRN with sildenafil PRN (P",
keywords = "As needed, Erectile dysfunction, On-demand, Once a day, Pharmacotherapy for erectile dysfunction, Sildenafil, Tadalafil",
author = "Eusebio Rubio-Aurioles and Hartmut Porst and Kim, {Edward D.} and Francesco Montorsi and Geoff Hackett and Morales, {Antonio Martin} and Bronwyn Stuckey and Hartwig Buttner and West, {Teena M.} and Huynh, {Ngan N.} and Enrique Lenero and Patrick Burns and Vladimir Kopernicky",
year = "2012",
month = "5",
doi = "10.1111/j.1743-6109.2012.02667.x",
language = "English",
volume = "9",
pages = "1418--1429",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction

AU - Rubio-Aurioles, Eusebio

AU - Porst, Hartmut

AU - Kim, Edward D.

AU - Montorsi, Francesco

AU - Hackett, Geoff

AU - Morales, Antonio Martin

AU - Stuckey, Bronwyn

AU - Buttner, Hartwig

AU - West, Teena M.

AU - Huynh, Ngan N.

AU - Lenero, Enrique

AU - Burns, Patrick

AU - Kopernicky, Vladimir

PY - 2012/5

Y1 - 2012/5

N2 - Aim. To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5mg once a day (OaD) vs. tadalafil 20mg or sildenafil 100mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men ≥18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were analyzed with a mixed effects model for crossover design. Main Outcome Measures. The primary outcome measure was the Sexual Self-Confidence domain of the Psychological and Interpersonal Relationship Scales (PAIRS) between tadalafil OaD and sildenafil PRN. Secondary Outcomes Included. Time Concerns and Spontaneity domains of PAIRS, and the Self-Esteem and Relationship (SEAR) scale. Results. Men naive to tadalafil OaD were enrolled (N=378), with 61-69% prior PDE5 inhibitor use. There were improvements in all PAIRS domains from baseline when comparing tadalafil OaD and PRN with sildenafil PRN (P

AB - Aim. To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5mg once a day (OaD) vs. tadalafil 20mg or sildenafil 100mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men ≥18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were analyzed with a mixed effects model for crossover design. Main Outcome Measures. The primary outcome measure was the Sexual Self-Confidence domain of the Psychological and Interpersonal Relationship Scales (PAIRS) between tadalafil OaD and sildenafil PRN. Secondary Outcomes Included. Time Concerns and Spontaneity domains of PAIRS, and the Self-Esteem and Relationship (SEAR) scale. Results. Men naive to tadalafil OaD were enrolled (N=378), with 61-69% prior PDE5 inhibitor use. There were improvements in all PAIRS domains from baseline when comparing tadalafil OaD and PRN with sildenafil PRN (P

KW - As needed

KW - Erectile dysfunction

KW - On-demand

KW - Once a day

KW - Pharmacotherapy for erectile dysfunction

KW - Sildenafil

KW - Tadalafil

UR - http://www.scopus.com/inward/record.url?scp=84860295435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860295435&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2012.02667.x

DO - 10.1111/j.1743-6109.2012.02667.x

M3 - Article

C2 - 22429760

AN - SCOPUS:84860295435

VL - 9

SP - 1418

EP - 1429

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 5

ER -